Pegorgotein

Drug Profile

Pegorgotein

Alternative Names: Dismutec; PEG-SOD; PEG-superoxide dismutase; Polyethylene glycol superoxide dismutase; WIN 22118

Latest Information Update: 26 Aug 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Enzon Pharmaceuticals
  • Class Oxidoreductases; Polyethylene glycols
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Craniocerebral trauma; Reperfusion injury; Stroke

Most Recent Events

  • 11 Jul 1997 Discontinued - Clinical trials for Stroke (unspecified route)
  • 08 Jul 1997 Sanofi Winthrop is no longer a licensee for pegorgotein
  • 08 Jul 1997 Discontinued-III for Head injuries in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top